Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: A null association

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2509-2511

  Hernandez, Rohini K ^a   Sørensen, Henrik Toft ^a,b   Jacobsen, Jacob ^b   Pedersen, Lars ^b   Lash, Timothy L ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CALCULATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGISTRY; DATA BASE; FEMALE; HAZARD RATIO; HEART FAILURE; HOSPITALIZATION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARTERIOSCLEROSIS; BREAST NEOPLASMS; DENMARK; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROPORTIONAL HAZARDS MODELS; RISK; TAMOXIFEN;

EID: 53349122296     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0570     Document Type: Article

References (21)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715-22.
3. Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9.
4. Thangaraju M, Kumar K, Gandhirajan R, et al. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 1994;73:659-63.
5. Cushman M, Costantino JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001;21:255-61.
6. McDonald CC, Steward HJ; for the Scottish Breast Cancer Committee. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991;303:435-7.
7. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignarn J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776-82.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
9. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001;93:16-21.
10. Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008;100:252-60.
11. Frank L. When an entire country is a cohort. Science 2000;287:2398-9.
12. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199-200.
13. Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast carcinoma patients and risk of acute myocardial infarction and newly-diagnosed angina. Cancer 2006;106:480-1.
14. Geiger AM, Chen W, Bernstein L. Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer 2005;92:1614-20.
15. Geiger AM, Fischberg GM, Chen W, Bernstein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96:1528-36.
16. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
17. NCCN Practice Guidelines in Oncology, Breast Cancer - v.2.2008. Invasive breast cancer, adjuvant endocrine therapy. http://www.nccn.org/professionals/ physician_gls/PDF/breast.pdf. Accessed January 29, 2008.
18. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
19. Perez EA. Appraising adjuvant aromatase inhibitor therapy. Oncologist 2006;11:1058-69.
20. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-30.
21. Johnsen SP, Overvad K, Sørensen HT, Tjønneland A, Husted SE. Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. J Clin Epidemiol 2002;55:602-7.